条条大路通罗马？

shiweibuyi

REP 9AC发展史

09年2月：REPLICor得到允许在乙肝和丙肝病人身上试验REP 9AC以决定其安全性和有效性。

REPLICor announced today that it has received approval to conduct an open label study of the safety and efficacy of its drug in patients with chronic hepatitis B and C in Asia.  Patients will receive escalating doses of the drug to determine a safe and effective dose of its drug for treating viral hepatitis in these patients.  Primary efficacy endpoints will include reduction in serum viral titers and serum surface antigen levels. Patient enrollment is underway.

shiweibuyi

REP 9AC发展史

09年3月：得到IRB允许后，REPLICor开始在病人身上进行REP 9AC的期一和期二试验。

Under its IRB-approved protocol, REPLICor initiated treatment of patients enrolled in its phase I / II trial with its drug.

shiweibuyi

REP 9AC发展史

09年3月31日：主要试验科学家，Dr. Andrew Vaillant，公布试验数据，其中包括在动物身上的HBV治愈应答。

Dr. Andrew Vaillant, VP, Operations and Chief Scientific Officer, has been invited to present REPLICor’s latest preclinical data on the use of its drug for the treatment of hepatitis B.  This presentation will include the latest data from REPLICor’s collaboration with the lab of Dr. Allison Jilbert and will demonstrate for the first time the achievement of a curative response to hepatitis B infection in a preclinical animal model using REPLICOR’s drug.

shiweibuyi

REP 9AC发展史

09年4月16日：和NIH肝病部合作的数据表明不同的APs能阻断鼠上HCV病毒，能防止病毒传染，容忍性好。

Data generated in collaboration with the Liver Diseases Branch of the NIH was published in the prestigious journal Gastroenterology.  The article presented data that demonstrated that numerous different amphipathic DNA polymers (APs) were effective in vitro against HCV infection from all known genotypes, using both JFH1 and pseudoparticle systems.  APs were shown to be able to effectively block the entry of HCV virions into the host cells.  Pre-clinical assessment of REP 9AC in HCV infected Scid-Hu mice demonstrated that the APs REP 9C and REP 9AC were able to provide effective protection from HCV infection and were well tolerated.



APs represent a new class of antiviral agent and may be an important new tool for prophylaxis in HCV+ liver transplant recipients and also for the treatment of chronic HCV infection.

shiweibuyi

REP 9AC发展史

09年12月8日：澳洲Dr. Allison Jilbert发表数据显示REP 9AC在HBV鸭身上有效迅速地清除乙肝表面抗原、3个星期内产生抗体，疗后16周的肝捡不能发现乙肝表面抗原、cccDNA减少200倍。

Dr. Allison Jilbert from University of Adelaide, Australia, will present our preclinical efficacy data on REP 9AC at the HEP DART 2009 conference to be held in Hawaii on December 6 – 10, 2009.  This conference is attended by hundreds of physicians and researchers from pharmaceutical companies and universities worldwide who are involved in multiple facets of drug development for viral hepatitis. See: http://www.informedhorizons.com/hepdart2009/program.aspx

REP 9AC is an amphipathic DNA polymer that was shown in vivo to be an effective suppressor of DHBsAg release into the serum. Four weeks of daily REP 9AC treatment in Pekin ducks persistently infected with DHBV demonstrated a rapid clearance of serum DHBsAg and detection of substantial anti-DHBsAg antibody titers within 3 weeks of initiation of treatment.  All ducks which acquired substantial anti-DHBsAg antibody titers by the end of 4 weeks of treatment (55%) also experienced a sustained virologic response for 16 weeks post-treatment, having no detectable serum DHBsAg or DHBV DNA in their serum.  Liver biopsies at 16 weeks post-treatment showed no detectable DHBsAg and genomic DHBV (cccDNA) was reduced more than 200 fold compared to pretreatment levels to 0.07copies/hepatocyte.



REP 9AC is the first antiviral agent to have achieved a sustained virologic response off treatment in the duck model and to show evidence of pronounced clearance of infection from the liver.  Moreover, the suppression of DHBsAg release has now been validated as a highly effective therapeutic modality which may have great clinical benefit in the treatment of chronic hepatitis B infection in humans.

shiweibuyi

REP 9AC发展史

10年3月18日：北京会上报告REP 9AC在6位乙肝病人身上试用，表面抗体迅速产生、表面抗原12周内被清除，疗效6个月后还保持。

Replicor will present results from its clinical proof of concept trial at the upcoming 20th annual meeting of the APASL in Beijing, China. This is the largest annual meeting dedicated to treatment of liver disease in Asia which typically attracts over 5,000 physicians and researchers. See: http://www.apasl2010beijing.org/en/index.aspx

Interim data on the efficacy of the amphipathic DNA polymer REP 9AC in the treatment of chronic hepatitis B in 6 patients will be presented. Interim results will show that REP 9AC treatment rapidly leads to the detection of anti-HBsAg antibodies and the reduction and or clearance of serum HBsAg within the first 12 weeks of treatment in human patients. These findings are associated with substantial and sustained reductions in serum HBV titers which may be due to an improved immune response to the infection. This is exemplified by the first patient who had 2,000,000 copies of the virus / ml in his blood, was then treated for a total of 23 weeks and who has so far maintained a sustained virologic response (<70 copies of the virus / ml in his blood) for a period of 6 months off treatment.

REP 9AC represents a new class of antiviral agent that blocks the release of HBsAg which has been associated with HBV-specific immune defects and may contribute to the long term persistence of the infection. It appears that REP 9AC effectively clears HBsAg in the serum and leads to the rapid acquisition of effective immunity against the infection.  REP 9AC may therefore provide an important new tool in the treatment of chronic hepatitis B.

[ 本帖最后由 shiweibuyi 于 2010-4-4 18:22 编辑 ]

shiweibuyi

钱放对地方不但生钱还能救命！

中国作为一经济飞跃的大国，不但有众多的因长年抗病毒而在经济上给压得喘不过气的乙肝病患，也不乏一批钱有的是只是苦于不能清除病毒、产生抗体的阔佬。

建议后者：让钱生钱，救命积德！

REPLICor是加拿大十大生化公司之一，却也欢迎投资者！研究资本雄厚，研究速度就会加快，10%的中国人就越早获救！当REP 9AC取代所有抗病毒药和干扰素时，阔佬们的回报会少吗？钱再多，要是乙肝病毒占了上风，那些钱有用吗？

有意帮助REP 9AC快速研发者可直接与Dr. Michel Bazinet联系：

Michel Bazinet, MD
Chairman of the Board and CEO
[email protected]
Tel.: (514) 496-9016

Investors

In order to accelerate the development of its drug, REPLICor is always on the lookout for private investors. We are developing a new antiviral drug that could revolutionize the way patients with chronic hepatitis B are treated. The drug could also have multiple additional applications in the treatment of other important viral infections.

REPLICor was nominated as one of Canada’s Top 10 Life Sciences Companies for the years 2004/2005 and for 2007/2008 by the Ottawa Centre for Research and Innovation.

See: http://www.topcanadiancompanies.ca/winners/alumni.pdf

If you are an accredited investor who would like to contribute to our development efforts and share in the rewards, please contact Dr. Michel Bazinet to obtain more information about the Company.

Michel Bazinet, MD
Chairman of the Board and CEO
[email protected]

Tel.: (514) 496-9016

渺小渺

很感谢楼主又为我们搜集了这么多的资料

REPLICor公司的工作效率也蛮高的，这么快就进入了人体试验

乙肝病毒最初是从澳大利亚发现的，希望澳大利亚的这种药物也可以成为乙肝的终结者，顶顶顶！！！！

佛光普照L

楼主大哥这消息是真的吗？准确吗？不想被忽悠了，我个人觉得蔡荣事件很可能忽悠了大家，希望你的消息是准确的，让我们大家把乙肝的帽子摘掉得以重生。

森林之气

Background: REP9AC is a DNA-based amphipathic polymer whose antiviral
activity is linked to targeting viral glycoproteins important for viral entry and/
or release. The preclinical evaluation of 28 days of REP 9AC therapy in ducks
persistently infected with DHBV demonstrated rapid clearance of DHBV
DNA, DHBsAg and rapid appearance of anti-DHBs antibodies in 55% of ducks
whose blood had no detectable evidence of DHBV infection 16 weeks after
cessation of REP 9AC therapy. The ability of REP 9AC to treat human patients
with CHB is currently being evaluated in a proof of concept trial.
Methods: Patients with CHB were subjected to REP9AC therapy administered
by slow continuous infusion. Safety and virologic response (HBV DNA,
HBsAg, anti-HBs) were assessed weekly, either at the trial site or by confirmatory
testing (HBsAg, HBeAg, anti-HBs, anti-HBe) of frozen serum samples
at a separate location using the ArchitectTM testing platform.
Results: Interim data has shown that all patients treated to date have cleared
HBsAg and developed protective immunity. Clearance of HBsAg anddevelopment of protective levels of anti-HBs occurred as early as 7 days following
initiation of treatment at higher doses. At the time of abstract submission,
one patient has already exhibited clear signs of a sustained virologic response
(HBV DNA -, HBsAg -, HBeAg -, anti-HBs +, anti-HBe +) for 8 continuous
weeks off treatment after receiving only 23 weeks of treatment with REP9AC.
Conclusions: These results demonstrate that amphipathic polymers are effective
in rapidly reducing HBsAg levels in CHB patients which allows patients to
seroconvert. The rapid appearance of anti-HBs and anti-HBe antibodies in these
patients, the best predictors of SVR in patients with CHB, suggest that amphipathic
polymers could become an important new tool in the treatment of CHB.